AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 19853700 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative rhythm control
Number of subjects: 2794
Study 19853700 — intervention group
Group type: EXPERIMENTAL
Intervention: Mortality or stroke at 30 days
Number of subjects: 2794
Study 19853700 — intervention group
Group type: EXPERIMENTAL
Intervention: Mortality at 3 years
Number of subjects: 2794
Study 15572876 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 31
Study 15572876 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 31
Study 15572876 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 31
Study 12791225 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical ophthalmic NSAIDs
Number of subjects: 0
Study 12791225 — intervention group
Group type: COMPARATOR
Intervention: Placebo eyedrops
Number of subjects: 0
Study 10203909 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine chip with scaling and root planing (SRP)
Number of subjects: 565
Study 10203909 — intervention group
Group type: COMPARATOR
Intervention: Placebo chip with scaling and root planing (SRP)
Number of subjects: 565
Study 8915645 — intervention group
Group type: EXPERIMENTAL
Intervention: ADCON-L Anti-Adhesion Barrier Gel
Number of subjects: 0
Study 1871184 — intervention group
Group type: EXPERIMENTAL
Intervention: Evening primrose oil (EPO) supplementation (45 mg GLA and 360 mg linoleic acid, 2 capsules daily for 4 months, then 4 capsules daily for 4 months)
Number of subjects: 11
Study 1871184 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsules
Number of subjects: 11
Study 6137500 — intervention group
Group type: COMPARATOR
Intervention: Prazosin (4 mg, 2 pills of Minipress Pfizer per day) for 7 days
Number of subjects: 22
Study 6137500 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 31425171 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist-led hypertension management program with barbers promoting follow-up and pharmacists prescribing antihypertensive therapy.
Number of subjects: 0
Study 31425171 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group).
Number of subjects: 0
Study 28194611 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D echocardiography-guided LV lead placement
Number of subjects: 47
Study 28194611 — intervention group
Group type: EXPERIMENTAL
Intervention: CRT insertion
Number of subjects: 47
Study 27779354 — intervention group
Group type: EXPERIMENTAL
Intervention: Parecoxib 0.25 mg·kg‐1
Number of subjects: 59
Study 27779354 — intervention group
Group type: EXPERIMENTAL
Intervention: Parecoxib 1 mg·kg‐1
Number of subjects: 59
Study 27779354 — intervention group
Group type: EXPERIMENTAL
Intervention: Parecoxib 2 mg·kg‐1
Number of subjects: 59
Study 27779354 — intervention group
Group type: EXPERIMENTAL
Intervention: Parecoxib (various doses)
Number of subjects: 59
Study 24314863 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey protein (10 g)
Number of subjects: 0
Study 24314863 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey protein (20 g)
Number of subjects: 0
Study 24314863 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose (10 g)
Number of subjects: 0
Study 24314863 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose (20 g)
Number of subjects: 0
Study 24314863 — intervention group
Group type: COMPARATOR
Intervention: Water (control)
Number of subjects: 0
Study 23018869 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-week sensory relearning home program
Number of subjects: 31
Study 23018869 — intervention group
Group type: COMPARATOR
Intervention: No further treatment (Control)
Number of subjects: 31
Study 19445432 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength training (n = 81)
Number of subjects: 163
Study 19445432 — intervention group
Group type: COMPARATOR
Intervention: Standard care (n = 82)
Number of subjects: 163
Study 17994473 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal cocaine (4, 20, 40, and 60 mg) during aripiprazole maintenance
Number of subjects: 8
Study 17994473 — intervention group
Group type: COMPARATOR
Intervention: Placebo during aripiprazole maintenance
Number of subjects: 8
Study 16400891 — intervention group
Group type: EXPERIMENTAL
Intervention: Epinephrine (2, 4, and 8 actuations administered at 17‐minute intervals)
Number of subjects: 8
Study 16400891 — intervention group
Group type: COMPARATOR
Intervention: Albuterol (6 cumulative actuations administered at 17‐minute intervals)
Number of subjects: 8
Study 16400891 — intervention group
Group type: EXPERIMENTAL
Intervention: Epinephrine
Number of subjects: 8
Study 16400891 — intervention group
Group type: COMPARATOR
Intervention: Albuterol
Number of subjects: 8
Study 11952198 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard treatment plus contingency management (CM)
Number of subjects: 42
Study 11952198 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 42
Study 9797799 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide
Number of subjects: 12
Study 9797799 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucagon
Number of subjects: 12
Study 9797799 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 8573426 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiludronate 400 mg/day for 3 months
Number of subjects: 0
Study 8573426 — intervention group
Group type: COMPARATOR
Intervention: Etidronate 400 mg/day
Number of subjects: 0
Study 2229455 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg velnacrine tid for 28 days
Number of subjects: 56
Study 2229455 — intervention group
Group type: COMPARATOR
Intervention: 25 mg velnacrine bid
Number of subjects: 56
Study 2229455 — intervention group
Group type: COMPARATOR
Intervention: 50 mg velnacrine bid
Number of subjects: 56
Study 2229455 — intervention group
Group type: COMPARATOR
Intervention: 100 mg velnacrine bid
Number of subjects: 56
Study 322533 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous diazepam
Number of subjects: 229
Study 322533 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 229
Study 30020401 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate volume aerobic exercise (150 min/week)
Number of subjects: 400
Study 30020401 — intervention group
Group type: COMPARATOR
Intervention: High volume aerobic exercise (300 min/week)
Number of subjects: 400
Study 30020401 — intervention group
Group type: COMPARATOR
Intervention: Women working full time
Number of subjects: 400
Study 30020401 — intervention group
Group type: COMPARATOR
Intervention: Increase in BMI by 1 kg/m2
Number of subjects: 400
Study 30020401 — intervention group
Group type: EXPERIMENTAL
Intervention: Increase in physical health
Number of subjects: 400
Study 28109107 — intervention group
Group type: EXPERIMENTAL
Intervention: rTMS treatment
Number of subjects: 178
Study 28109107 — intervention group
Group type: COMPARATOR
Intervention: Sham rTMS treatment (Control)
Number of subjects: 178
Study 26056438 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-threshold physical activity program (60 minutes weekly for 20 weeks)
Number of subjects: 222
Study 26056438 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention specified)
Number of subjects: 222
Study 22680774 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive chemotherapy (i.v., mg/m(2), vindesine 5, adriamycin 90, BCNU 140, etoposide 600, methylprednisolone 600) before radiotherapy (RT)
Number of subjects: 269
Study 22680774 — intervention group
Group type: EXPERIMENTAL
Intervention: Three or four cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) followed by RT
Number of subjects: 269
Study 22680774 — intervention group
Group type: COMPARATOR
Intervention: Historical control group (HCG) in CR after three ABVD cycles before RT
Number of subjects: 269
Study 22232850 — intervention group
Group type: EXPERIMENTAL
Intervention: Etoricoxib 60 mg (test product: Etocox-60)
Number of subjects: 24
Study 22232850 — intervention group
Group type: COMPARATOR
Intervention: Etoricoxib 60 mg (reference product)
Number of subjects: 24
Study 22232850 — intervention group
Group type: COMPARATOR
Intervention: Etoricoxib 60 mg (test product: Etocox-60) and reference product
Number of subjects: 24
Study 19770831 — intervention group
Group type: EXPERIMENTAL
Intervention: Cavinton 30 mg/day for 90 days (2 courses per year) in addition to basic therapy
Number of subjects: 138
Study 19770831 — intervention group
Group type: COMPARATOR
Intervention: Basic therapy only
Number of subjects: 138
Study 19770831 — intervention group
Group type: EXPERIMENTAL
Intervention: Cavinton treatment
Number of subjects: 138
Study 16478572 — intervention group
Group type: EXPERIMENTAL
Intervention: GDS-30 (cut-off 14/15)
Number of subjects: 392
Study 16478572 — intervention group
Group type: COMPARATOR
Intervention: Classical GHQ (cut-off 4/5)
Number of subjects: 392
Study 16478572 — intervention group
Group type: COMPARATOR
Intervention: Likert GHQ (cut-off 15/16)
Number of subjects: 392
Study 16478572 — intervention group
Group type: COMPARATOR
Intervention: c-GHQ (cut-off 5/6)
Number of subjects: 392
Study 12044619 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained-release morphine (20mg/d titrated to a maximum of 180mg/d)
Number of subjects: 49
Study 12044619 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study 10210123 — intervention group
Group type: EXPERIMENTAL
Intervention: Hispanic live births
Number of subjects: 0
Study 10210123 — intervention group
Group type: COMPARATOR
Intervention: Non-Hispanic European live births
Number of subjects: 0
Study 7842195 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygen therapy
Number of subjects: 0
Study 7842195 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopamine
Number of subjects: 0
Study 7842195 — intervention group
Group type: EXPERIMENTAL
Intervention: Both therapies (Oxygen and Dopamine)
Number of subjects: 0
Study 7842195 — intervention group
Group type: COMPARATOR
Intervention: Control (Air)
Number of subjects: 0
Study 7842195 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygen
Number of subjects: 0
Study 2371429 — intervention group
Group type: EXPERIMENTAL
Intervention: Oscillometry
Number of subjects: 27
Study 2371429 — intervention group
Group type: COMPARATOR
Intervention: Passive anterior rhinomanometry
Number of subjects: 27
Study 2371429 — intervention group
Group type: COMPARATOR
Intervention: Active anterior rhinomanometry
Number of subjects: 27
Study 2371429 — intervention group
Group type: COMPARATOR
Intervention: Active posterior rhinomanometry
Number of subjects: 27
Study 731810 — intervention group
Group type: EXPERIMENTAL
Intervention: estramustine-17-phosphate (600 mg daily for at least 3 months)
Number of subjects: 0
Study 731810 — intervention group
Group type: COMPARATOR
Intervention: 2.6‐cis-diphenylhexamethylcyclotetrasiloxane (300 mg daily for at least 3 months)
Number of subjects: 0
Study 731810 — intervention group
Group type: COMPARATOR
Intervention: 2.6‐cis-diphenylhexamethylcyclotetrasiloxane (non-randomized group)
Number of subjects: 0
Study 31880963 — intervention group
Group type: EXPERIMENTAL
Intervention: Erector Spinae Plane Block (ESPB)
Number of subjects: 60
Study 31880963 — intervention group
Group type: COMPARATOR
Intervention: Conventional Analgesia (CA)
Number of subjects: 60
Study 29398993 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin 150 mg daily
Number of subjects: 86
Study 29398993 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86
Study 27537670 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual clinical simulation
Number of subjects: 56
Study 27537670 — intervention group
Group type: COMPARATOR
Intervention: Face-to-face high fidelity manikin simulation
Number of subjects: 56
Study 25295709 — intervention group
Group type: EXPERIMENTAL
Intervention: Procalcitonin (PCT) algorithm with 0.1 ng/ml cut-off
Number of subjects: 400
Study 25295709 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 400
Study 25295709 — intervention group
Group type: EXPERIMENTAL
Intervention: Procalcitonin (PCT) algorithm
Number of subjects: 400
Study 23768664 — intervention group
Group type: EXPERIMENTAL
Intervention: In-Home Cognitive Behavioral Therapy (IH-CBT)
Number of subjects: 93
Study 23768664 — intervention group
Group type: COMPARATOR
Intervention: Standard Home Visitation (SHV)
Number of subjects: 93
Study 20799286 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical bowel preparation (MBP)
Number of subjects: 42
Study 20799286 — intervention group
Group type: COMPARATOR
Intervention: No mechanical bowel preparation (no-MBP)
Number of subjects: 42
Study 18548362 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-alanine (4.8 g per day)
Number of subjects: 8
Study 18548362 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 15706558 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole body vibration plus physical therapy (PT)
Number of subjects: 42
Study 15706558 — intervention group
Group type: COMPARATOR
Intervention: Physical therapy alone
Number of subjects: 42
Study 12362285 — intervention group
Group type: EXPERIMENTAL
Intervention: IVUS guidance
Number of subjects: 43
Study 12362285 — intervention group
Group type: COMPARATOR
Intervention: ANGIO guidance
Number of subjects: 43
Study 9525795 — intervention group
Group type: EXPERIMENTAL
Intervention: Outreach case management services in addition to standard aftercare service
Number of subjects: 292
Study 9525795 — intervention group
Group type: COMPARATOR
Intervention: Standard aftercare services only
Number of subjects: 292
Study 7698053 — intervention group
Group type: EXPERIMENTAL
Intervention: 9 g of fish oil
Number of subjects: 40
Study 7698053 — intervention group
Group type: EXPERIMENTAL
Intervention: 18 g of fish oil
Number of subjects: 40
Study 7698053 — intervention group
Group type: COMPARATOR
Intervention: 9 g of corn oil
Number of subjects: 40
Study 7698053 — intervention group
Group type: COMPARATOR
Intervention: 18 g of corn oil
Number of subjects: 40
Study 7698053 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil (both dosages)
Number of subjects: 40
Study 7698053 — intervention group
Group type: COMPARATOR
Intervention: Fish oil and corn oil
Number of subjects: 40
Study 2655680 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous methylprednisolone sodium succinate (MPSS) at doses of 20, 40, and 80 mg
Number of subjects: 5
Study 2655680 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral methylprednisolone (20 mg as 4 x 5 mg tablets)
Number of subjects: 5
Study 11717 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam (4 mg)
Number of subjects: 95
Study 11717 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 95
Study 11717 — intervention group
Group type: COMPARATOR
Intervention: Diazepam (10 mg)
Number of subjects: 95
Study 31285821 — intervention group
Group type: EXPERIMENTAL
Intervention: WHO EBHR formulation with 0.5% glycerol
Number of subjects: 40
Study 31285821 — intervention group
Group type: COMPARATOR
Intervention: WHO EBHR formulation without glycerol (0%)
Number of subjects: 40
Study 31285821 — intervention group
Group type: COMPARATOR
Intervention: WHO EBHR formulation with 1.45% glycerol
Number of subjects: 40
Study 31285821 — intervention group
Group type: COMPARATOR
Intervention: WHO EBHR formulation with 0.75% glycerol
Number of subjects: 40
Study 27831503 — intervention group
Group type: EXPERIMENTAL
Intervention: cisplatin-paclitaxel plus CADI-05 (chemoimmunotherapy group)
Number of subjects: 221
Study 27831503 — intervention group
Group type: COMPARATOR
Intervention: cisplatin-paclitaxel (chemotherapy group)
Number of subjects: 221
Study 26432510 — intervention group
Group type: EXPERIMENTAL
Intervention: DHA-rich fish-oil supplementation during pregnancy
Number of subjects: 0
Study 26432510 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study 23814241 — intervention group
Group type: EXPERIMENTAL
Intervention: NA-QS
Number of subjects: 100
Study 23814241 — intervention group
Group type: COMPARATOR
Intervention: QS
Number of subjects: 100
Study 23814241 — intervention group
Group type: COMPARATOR
Intervention: MP
Number of subjects: 100
Study 21099725 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone within 24 hours
Number of subjects: 829
Study 21099725 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone within 25 to 48 hours
Number of subjects: 829
Study 21099725 — intervention group
Group type: COMPARATOR
Intervention: No prednisolone (control group) within 24 hours
Number of subjects: 829
Study 21099725 — intervention group
Group type: COMPARATOR
Intervention: No prednisolone (control group) within 25 to 48 hours
Number of subjects: 829
Study 21099725 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone for patients aged 40 years or older
Number of subjects: 829
Study 21099725 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone for patients aged younger than 40 years
Number of subjects: 829
Study 18851956 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin (10 mg/day for 4 weeks)
Number of subjects: 136
Study 17518508 — intervention group
Group type: COMPARATOR
Intervention: Cinacalcet (90 mg) alone
Number of subjects: 24
Study 17518508 — intervention group
Group type: EXPERIMENTAL
Intervention: Cinacalcet (90 mg) with ketoconazole (200 mg twice daily for 7 days)
Number of subjects: 24
Study 17518508 — intervention group
Group type: EXPERIMENTAL
Intervention: Cinacalcet (90 mg) with ketoconazole
Number of subjects: 24
Study 15451121 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment for nicotine dependence
Number of subjects: 211
Study 11439378 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin biopsy at the proximal thigh and distal leg in ganglionopathy patients
Number of subjects: 47
Study 11439378 — intervention group
Group type: COMPARATOR
Intervention: Skin biopsy at the proximal thigh and distal leg in axonal neuropathy patients
Number of subjects: 47
Study 11439378 — intervention group
Group type: COMPARATOR
Intervention: Skin biopsy at the proximal thigh and distal leg in healthy subjects
Number of subjects: 47
Study 9879639 — intervention group
Group type: EXPERIMENTAL
Intervention: 14C-delmopinol mouth rinse (10-ml aqueous solution at 2 mg/ml)
Number of subjects: 12
Study 9879639 — intervention group
Group type: EXPERIMENTAL
Intervention: 14C-delmopinol oral dose
Number of subjects: 12
Study 8020806 — intervention group
Group type: EXPERIMENTAL
Intervention: Amino acid based diet containing 3% fat
Number of subjects: 40
Study 8020806 — intervention group
Group type: COMPARATOR
Intervention: Peptide based diet containing 33% fat
Number of subjects: 40
Study 8020806 — intervention group
Group type: EXPERIMENTAL
Intervention: Both diets
Number of subjects: 40
Study 31742932 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonabsorbable Merocel packs (packing type A)
Number of subjects: 40
Study 31742932 — intervention group
Group type: COMPARATOR
Intervention: Propel steroid eluting stents (packing type B)
Number of subjects: 40
Study 29225152 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenosine (postconditioning group)
Number of subjects: 60
Study 29225152 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 60
Study 27634660 — intervention group
Group type: EXPERIMENTAL
Intervention: Sexual health care nursing record
Number of subjects: 24
Study 27634660 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 24
Study 24063263 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary intraocular lens (IOL) implantation
Number of subjects: 40
Study 24063263 — intervention group
Group type: COMPARATOR
Intervention: Secondary intraocular lens (IOL) implantation
Number of subjects: 40
Study 22627166 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose haloperidol
Number of subjects: 498
Study 22627166 — intervention group
Group type: EXPERIMENTAL
Intervention: Amisulpride
Number of subjects: 498
Study 22627166 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 498
Study 22627166 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine
Number of subjects: 498
Study 22627166 — intervention group
Group type: EXPERIMENTAL
Intervention: Ziprasidone
Number of subjects: 498
Study 22627166 — intervention group
Group type: COMPARATOR
Intervention: All treatment groups
Number of subjects: 498
Study 20141367 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate 70 mg once weekly for 1 year
Number of subjects: 2
Study 20141367 — intervention group
Group type: COMPARATOR
Intervention: Risedronate 35 mg once weekly for 1 year
Number of subjects: 2
Study 19902897 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard design NexGen Legacy Posterior-Stabilized TKA
Number of subjects: 56
Study 19902897 — intervention group
Group type: EXPERIMENTAL
Intervention: High-flexion design NexGen Legacy Posterior-Stabilized TKA
Number of subjects: 56
Study 19902897 — intervention group
Group type: EXPERIMENTAL
Intervention: Soft tissue release
Number of subjects: 56
Study 19902897 — intervention group
Group type: EXPERIMENTAL
Intervention: Type of femoral component
Number of subjects: 56
Study 19902897 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative and intraoperative range of flexion
Number of subjects: 56
Study 17042906 — intervention group
Group type: EXPERIMENTAL
Intervention: Low amplitude vibration (30 Hz, 1.5 mm peak-to-peak amplitude)
Number of subjects: 9
Study 17042906 — intervention group
Group type: EXPERIMENTAL
Intervention: High amplitude vibration (30 Hz, 3 mm peak-to-peak amplitude)
Number of subjects: 9
Study 17042906 — intervention group
Group type: COMPARATOR
Intervention: Non-vibration condition (control)
Number of subjects: 9
Study 12957560 — intervention group
Group type: COMPARATOR
Intervention: Healthy elderly adults walking over obstacles
Number of subjects: 0
Study 12957560 — intervention group
Group type: EXPERIMENTAL
Intervention: Elderly patients with balance disorders walking over obstacles
Number of subjects: 0
Study 10969426 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly home-based intervention
Number of subjects: 171
Study 10969426 — intervention group
Group type: COMPARATOR
Intervention: Control (brief monthly tracking visits)
Number of subjects: 171
Study 9102666 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple insulin therapy
Number of subjects: 219
Study 9102666 — intervention group
Group type: COMPARATOR
Intervention: Conventional insulin therapy
Number of subjects: 219
Study 9102666 — intervention group
Group type: EXPERIMENTAL
Intervention: Hb A(1c) levels
Number of subjects: 219
Study 9102666 — intervention group
Group type: EXPERIMENTAL
Intervention: Evolution time of IDDM
Number of subjects: 219
Study 8416458 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone 250 mg IM
Number of subjects: 252
Study 8416458 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin 3 g orally plus probenecid 1 g orally
Number of subjects: 252